Merck & Co., Inc. Release: In New Data at One Year, JANUVIA(TM), An Investigational Medicine For Type 2 Diabetes, Demonstrated Substantial Glucose-Lowering Effect, With Significant Differences Compared To Glipizide (A Sulfonylurea) In Weight Change and Hy

WASHINGTON--(BUSINESS WIRE)--June 13, 2006--Merck & Co., Inc. (NYSE:MRK - News):In This Non-Inferiority Study, the Reduction in A1C Was Identical Between the Two Groups at 52 Weeks; Also, Patients on JANUVIA Once Daily had Significant Weight Loss (vs. Weight Gain on Glipizide) and a Significantly Lower Incidence of Hypoglycemia vs. Glipizide

Back to news